$66.50

2.15 (3.34%)

2/9/2010 3:59 PM

Bayer AG (ADR) (BAYRY.PK)

CAPS Rating:

The Company offers products, including ethical pharmaceuticals and other health care products, agricultural products and polymers.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating BAYRY.PK

Add Stock to Watchlist

What the Community Thinks

Total Members

222 Outperforms

7 Underperforms

All-Stars

61 Outperforms

2 Underperforms

Wall Street

4 Outperforms

0 Underperforms

Members bullish on BAYRY.PK are also bullish on:

Members bearish on BAYRY.PK are also bearish on:

Ticker Tags

Defensive (1457), Germany (25), It's a Noun! (69), Pharmaceuticals (149), International Stock (684), Healthcare (711), Mega Cap (110)
Suggest a tag

Bayer AG (ADR) At A Glance

Current Price:	$66.50
Last Trade Time:	2/9/2010 3:59 PM
Open:	$65.25
Previous Close:	$64.35
Daily Range:	$65.25 - $67.08
52-Week Range:	$42.65 - $81.60
Volume:	32,905
Market Cap:	$56.65B
P/E Ratio:	357.50
Compare Our Special Broker Offers!

Stock Trends

BAYRY.PK VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

5 Bayer AG (ADR) (BAYRY.PK)

Avatar NetscribePhrmtcl (96.01) Submitted: 1/31/07 6:55 AM

Bayer AG, which created aspirin, is involved worldwide in the discovery, development and marketing of several essential healthcare products, agricultural products for crop protection and animal health and specialty materials.

The company was able to record a strong top line growth of 26% in the th...More

Replies: 1 | Reply | Permalink

Bayer AG, which created aspirin, is involved worldwide in the discovery, development and marketing of several essential healthcare products, agricultural products for crop protection and animal health and specialty materials.

The company was able to record a strong top line growth of 26% in the third quarter purely driven by favorable acquisition of Schering AG. Its healthcare segment would continue to drive its top line in the upcoming year as the company does not have too many worries about patent expiries in the near future except for one of its key drug called Adalat.

Moreover, its newly launched drug Nexavar for the treatment of advanced renal cell carcinoma has received promising response. Nexavar is also undergoing clinical trial for several other indications like Melanoma and kidney cancer and looking at the rapidly growth market for oncology; this drug is set to emerge as a potential blockbuster in the years to come.

The company has decent product pipeline with major investigational drugs like Rivaroxaban and BAY 79-4980. Rivaroxaban for the treatment of thrombosis which is undergoing early Phase III trial is not expected to hit the market before 2010. Although this investigational drug has huge market opportunity, one cannot be certain about the prospects to this drug as it could face competition from other investigational drugs like Eli Lilly’s LY517717 and Bristol Myers Squibb’s DPC-423 which could be launched around the same time as Rivaroxaban.

As a part of the growth strategy, the company has undertaken collaboration with US biotech company Regeneron to strengthen its specialty pharmaceuticals division. In order to strengthen its OTC consumer business, it has acquired an OTC company in China. It has also recently opened one of its biggest polycarbonate plants in China to exploit the growth potential in a highly promising market. One concern for the company in the year ahead is going to be the challenge to arrest the decline in the sales from CropScience segment. However, the continued growth in healthcare and material science segments are expected to offset the same and drive the company forward.

Top Bear Pitch

Recs

1 Bayer AG (ADR) (BAYRY.PK)

Avatar TRGoodvsEvil (< 20) Submitted: 7/03/09 8:02 PM

This portfolio tracks the performance of good vs. evil companies.

Evil attributes:
-4th largest toxic polluter in the world (http://www.peri.umass.edu/toxic100_index/)
-Inventor of mustard gas and heroin
-Nazi Fritz ter Meer became chairman of Bayer after having been sentenced at Nuremberg trials
...More

Replies: 0 | Reply | Permalink

CAPS Members

Show Me:

Sort by:

picks per page. CHANGE

Results 1 - 5 of 30 : 1 2 3 4 5 Next »

Recs 1 (BAYRY.PK) TRGoodvsEvil (< 20) Submitted: 7/03/09 8:02 PM : Start Price: $51.65 BAYRY.PK Score: -7.62 This portfolio tracks the performance of good vs. evil companies. Evil attributes: -4th largest toxic polluter in the world (http://www.peri.umass.edu/toxic100_index/) -Inventor of mustard gas and heroin -Nazi Fritz ter Meer became chairman of Bayer after having been sentenced at Nuremberg trials -Supply antibiotics to livestock, creating dangerous antibiotic-resistant bacteria -According to lawsuit, knowingly sold HIV-tainted blood products Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (BAYRY.PK) leaderoftheback (90.31) Submitted: 10/21/08 6:29 PM : Start Price: $62.85 BAYRY.PK Score: -7.00 Same pitch for all of my healthcare picks...headwinds are keeping the sector down, but expect the healthcare world to outperform as the market smoothes out, particularly those with good dividends. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (BAYRY.PK) jfontanot (< 20) Submitted: 10/18/08 3:41 PM : Start Price: $53.12 BAYRY.PK Score: 7.17 Panic has beaten this solid company with really good products. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (BAYRY.PK) halcyonsusan (< 20) Submitted: 7/01/08 2:38 PM : Start Price: $82.95 BAYRY.PK Score: -6.01 good portfolio of products and a well-run company Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (BAYRY.PK) msncapsid (< 20) Submitted: 4/29/08 11:34 AM : Start Price: $84.35 BAYRY.PK Score: -1.11 health products, we will always need Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Results 1 - 5 of 30 : 1 2 3 4 5 Next »

Wall Street

Results 1 - 4 of 4

picks per page. CHANGE Expand All Pitches Collapse All Pitches

Top Pick	Member Name	Member Rating	Start Date	Call	Time Frame	Start Price	Stock Gain	S&P Gain	Score	Pitch
	TrackEdwardOwens	98.91	02/27/09		5Y	$47.37	+40.38%	+47.40%	-7.02
	TrackBearStearns	84.85	09/14/07		NS	$76.18	-12.71%	-23.94%	+11.23
	TrackJPMorgan	84.76	06/06/07		NS	$71.26	-6.68%	-25.87%	+19.19
	TrackUBS	87.99	03/08/07		NS	$54.77	+21.42%	-19.03%	+40.44

Results 1 - 4 of 4

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.